Diabetes · Corpus Christi, TX
Diabetes studies in Corpus Christi, TX
6 recruiting studies have a site in Corpus Christi.
6 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company
- Location
- Corpus Christi, TX + 11 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- Corpus Christi, TX + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Eli Lilly and Company
- Location
- Corpus Christi, TX + 3 other US sites
- Eligibility basics
- Ages 1–35
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Corpus Christi, TX + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Amgen
- Location
- Corpus Christi, TX + 30 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
Estar Medical dba Medical Technologies, LTD
- Location
- Corpus Christi, TX + 1 other US site
- Eligibility basics
- Ages 18–80
Who these studies look for
Studies commonly set an HbA1c range, a diagnosis duration and a list of allowed or excluded medications. Some also recruit people without diabetes as a comparison group.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.